UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

ACLARIS THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.00001 PER SHARE

(Title of Class of Securities)

00461U105

(CUSIP Number)

FEBRUARY 5, 2024

(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 \square Rule 13d-1(b)

☑ Rule 13d-1(c)

 \square Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

CUSIP	No. 00461U105	SCHEDULE 13G	Page 2 of 10				
1 2 3 4	NAMES OF REPORTING PERSONS Millennium Management LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) □ SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION						
	Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	SOLE VOTING POWER -0- SHARED VOTING POWER 3,769,926 SOLE DISPOSITIVE POWER -0- SHARED DISPOSITIVE POWER 3,769,926 3,769,926					
9 10 11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,769,926 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
12	00						

CUSIP	No. 00461U105	SCHEDULE 13G	Page	3	of	10	
1	NAMES OF REPORTING PERSONS Millennium Group Management LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)						
3	(a) \Box (b) \Box SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
	PERSON WITH	5 SOLE VOTING POWER -0-					
		6 SHARED VOTING POWER 3,769,926					
		7 SOLE DISPOSITIVE POWER -0-					
		8 SHARED DISPOSITIVE POWER 3,769,926					
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,769,926						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.3% TYPE OF REPORTING PERSON OO						
12							

CUSIP N	0.
---------	----

SCHEDULE 13G

Page

4 of 10

	NAMES OF REPORTING PERSONS					
1	Iaraal A. Englandar					
┝───	Israel A. Englander CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
2	(a) \Box					
<u> </u>	(b) \square					
3	SEC USE ONLY					
	CITIZENSHIP OR PLACE OF ORGANIZATION					
4						
	United States	United States				
			SOLE VOTING POWER			
		5				
	NUMBER OF		-0-			
	SHARES	6	SHARED VOTING POWER			
	BENEFICIALLY					
	OWNED BY		3,769,926			
	EACH	7	SOLE DISPOSITIVE POWER			
	REPORTING PERSON WITH	/	-0-			
		8	SHARED DISPOSITIVE POWER			
			3,769,926			
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
9						
	3,769,926					
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
10						
	DED CENT OF CLASS DEDDESENTED DV AMOUNT IN DOW (0)					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	5.3%					
	TYPE OF REPORTING PERSON					
12						
	IN					

CUSIP No.		00461U105 SCHED	ULE 13G	Page [5	of	10	
Item 1.	(a)	Name of Issuer:						
		Aclaris Therapeutics, Inc.						
	(b)	Address of Issuer's Principal Executive Offices:						
		701 Lee Road, Suite 103 Wayne, Pennsylvania 19087						
<u>Item 2.</u>	(a) (b) (c)	<u>Name of Person Filing</u> : <u>Address of Principal Business Office</u> : <u>Citizenship</u> :						
		Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware						
		Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware						
		Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: United States						
	(d)	Title of Class of Securities:						
		common stock, par value \$0.00001 per share ("Common Sto	ock")					
	(e)	CUSIP Number:						
		00461U105						
Item 3. If thi	is state	ment is filed pursuant to Rule 13d-1(b), or 13d-2(b), check wh	ether the person filing is a:					
(a)		Broker or dealer registered under section 15 of the Act (15 U.S.	S.C. 780);					

- (b) \square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) \Box Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) 🛛 Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) \square An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
- (f) \Box An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

CUSIP No.

00461U105

SCHEDULE 13G

Page 6 of 10

(g) \square A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

(h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) \Box Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:

See response to Item 9 on each cover page.

(b) Percent of Class:

See response to Item 11 on each cover page.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

See response to Item 5 on each cover page.

SCHEDULE 13G

(ii) Shared power to vote or to direct the vote

See response to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of

See response to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of

See response to Item 8 on each cover page.

The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group

See Exhibit I.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

10

of

Page

CUSIP No.

00461U105

Page 8 of 10

Exhibits:

Exhibit I: Joint Filing Agreement, dated as of February 13, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

SCHEDULE 13G



SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: February 13, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel

/s/ Israel A. Englander Israel A. Englander

SCHEDULE 13G

Page 10 of 10

EXHIBIT I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value \$0.00001 per share, of Aclaris Therapeutics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: February 13, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel

/s/ Israel A. Englander Israel A. Englander